Last Price
14.20
Today's Change
0.00 (0.00%)
Day's Change
0.00 - 0.00
Trading Volume
0
Overview
Market Cap
0
Shares Outstanding
0
Avg Volume
0
Avg Price (50 Days)
0.00
Avg Price (200 Days)
0.00
PE Ratio
0.00
EPS
0.00
Earnings Announcement
Previous Close
0.00
Open
0.00
Day's Range
0.0 - 0.0
Year Range
0.0 - 0.0
Trading Volume
0
Price Change Highlight
1 Day Change
5 Day Change
1 Month Change
3 Month Change
6 Month Change
Ytd Change
1 Year Change
3 Year Change
5 Year Change
10 Year Change
Max Change
News and Blogs
No result.
Company Profile
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Latest Videos
![[New IPO] Icents Group Holdings Berhad, a specialised construction company focused on cleanroom EPCC services for industries, plans to list on the Ace Market!](https://mqac.i3investor.com/img/video_thumbnail/1192/Thumbnail__(9).png)
![[New IPO] A1 A.K. Koh Group Berhad, a well-established brand owner in the processed F&B industry, plans to list on the Ace Market!](https://mqac.i3investor.com/img/video_thumbnail/1186/Thumbnail__(8).png)
![[New IPO] PMCK Berhad, a healthcare services provider, plans to list on the Ace Market!](https://mqac.i3investor.com/img/video_thumbnail/1180/Thumbnail__(7).png)
Apps
Top Articles
Daily Stocks
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
